Subcutaneous implantable venous access device erosion through the skin in patients treated with anti-vascula endothelial growth factor therapy: a case series

Subcutaneous implantable venous access devices (IVADs) are commonly used in oncology practice. They facilitate the administration of chemotherapy, fluids and blood products. The incidence of IVAD-related complications is not uncommon, and includes infection, thrombosis and bleeding. IVAD erosion through the skin has been reported secondary to infection or inexperienced handling. We report three cases of IVAD erosion through the skin in patients treated with anti-vascular endothelial growth factor therapy. Anti-vascular endothelial growth factor agents are increasingly used in the treatment of solid tumors. This class of drugs has been associated with delayed wound healing and thromboembolism. To our knowledge, this is the first case series of IVAD erosion through skin, in patients receiving such therapy.